Search

Displaying results 5061 - 5070 of 5449 in total
  1. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated blood glucose levels, and to also av...

  2. Drug

    Adomiparin

    go.drugbank.com/drugs/DB06005
    Investigational

  3. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission. The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.

    Synonyms: WT-1 analog peptide vaccine
  4. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxyge...

  5. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  6. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  7. Drug

    Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10774
    ApprovedInvestigationalWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  8. Drug

    Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10775
    ApprovedInvestigationalWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  9. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10792
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  10. Drug

    Influenza A virus A/Bolivia/559/2013 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB11034
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it